Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DTC Guidance Should Include “Consumerized” Risk Terms, AstraZeneca Says

Executive Summary

FDA should establish a list of consumer-friendly medical terms to be used in risk information for product advertisements, AstraZeneca said

You may also be interested in...



FDA Disease Awareness Ad Policy Is Unfair To Small Firms, BIO Says

Restrictions on disease awareness advertisements proposed by FDA will hurt small biotech firms, the Biotechnology Industry Organization said

FDA Disease Awareness Ad Policy Is Unfair To Small Firms, BIO Says

Restrictions on disease awareness advertisements proposed by FDA will hurt small biotech firms, the Biotechnology Industry Organization said

FDA Releases DTC Guidances; “Not The Last Word” On Ads, McClellan Says

FDA's publication of three draft guidances on direct-to-consumer advertising is unlikely to relieve pressure on the agency to explain its approach to enforcement actions against drug manufacturers that repeatedly run false and misleading promotions

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS044105

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel